Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

– ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – LOS ANGELES, March 29, 2023 /PRNewswire/ — Athos Therapeutics, Inc. (“Athos”), a clinical stage…